艾德生物(300685.SZ):2020年度拟申请累计总额不超5亿元的综合授信额度
格隆汇4月13日丨艾德生物(300685.SZ)公布,公司第二届董事会第十二次会议召开,审议通过《关于2020年度公司向银行申请综合授信额度的议案》。
为了满足公司生产经营及未来发展需要,2020年度公司拟向银行申请累计总额不超过5亿元人民币(或等值外币)的综合授信额度(最终以各银行实际核准的信用额度为准),上述综合授信额度,主要用于短期流动资金贷款、银行承兑汇票、国内信用证、涉外信用证等业务。以上综合授信额度不等于公司的实际融资金额,公司具体融资金额将根据自身运营的实际需求确定。上述综合授信事项的期限为一年,自2019年度股东大会通过之日起至2020年度股东大会召开日止。授权公司董事长签署相关文件。
该议案尚需提交公司2019年度股东大会审议。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.